We are live on ! Find out more
CAPR icon

Capricor Therapeutics

56 hedge funds and large institutions have $32.7M invested in Capricor Therapeutics in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

175% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $377K

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

64% more capital invested

Capital invested by funds: $19.9M → $32.7M (+$12.8M)

51% more funds holding

Funds holding: 3756 (+19)

2.14% more ownership

Funds ownership: 13.21%15.35% (+2.1%)

Holders
56
Holders Change
+19
Holders Change %
+51.35%
% of All Funds
0.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
17
Reduced
8
Closed
5
Calls
$1.03M
Puts
$377K
Net Calls
+$658K
Net Calls Change
-$249K

CAPR Hedge Fund Activity: Q1 2024 in Review

56 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2024, worth a combined $32.7M — up 64% from $19.9M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CAPR positions and 5 closed out — a net gain of 19 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.32M. The largest seller was Woodline Partners, cutting an estimated $4.34M.

  • 56 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2024, up from 37 in Q4 2023.
  • Funds reported $32.7M of Capricor Therapeutics stock for Q1 2024, up 64% quarter-over-quarter.
  • 24 funds opened new Capricor Therapeutics positions in Q1 2024 and 5 closed out, a net change of +19 holders.
  • The largest Capricor Therapeutics buyer in Q1 2024 was Millennium Management, an estimated $1.32M added.
  • The largest Capricor Therapeutics seller in Q1 2024 was Woodline Partners, an estimated $4.34M sold.

Based on aggregated 13F filings for Q1 2024.